AstraZeneca’s top-selling product, Crestor (rosuvastatin), is looking shaky after results from SATURN, a head-to-head study pitting the statin against Pfizer’s soon-to-go-generic Lipitor (atorvastatin), were toplined today, leaving the $5.7 billion drug bereft of superior efficacy boasting rights.
To ease the plight of limited face time that sales reps are granted by physicians, AbelsonTaylor (AT) has created an interactive detailing platform for the iPad, coined eVE (electronic visualization engine), which allows marketing teams to communicate personalized brand experiences with the flick of a finger.
Auxilium, BioSpecifics Technologies to invest in cellulite indication for Xiaflex
Auxilium Pharmaceuticals has announced plans to invest in an indication for prescription drug Xiaflex (collagenase clostridium histolyticum), which was approved by FDA in February 2010 for adult Dupuytren’s contracture patients with a palpable cord, for the treatment of cellulite.
Mayo Clinic turns to social networking to recruit patients for SCAD study
Non-profit medical research organization Mayo Clinic took a new approach recently when recruiting participants for a study on spontaneous coronary artery dissection (SCAD) by utilizing social networks and social media.
Healthcare marketing agency inVentiv Health has further extended its breadth of services to the European market with the launch of a new shop called inVentiv Health Communications/Europe.
Google to pay $500 million in online pharma ad settlement
Google Inc. has agreed to a $500 million payout to the US government, following a Department of Justice (DOJ) investigation which found that Canadian pharmacies were illegally selling prescription drugs to American consumers via ads distributed by the search giant’s advertising arm, Google AdWords.
Majority of pharma journal ads not FDA-compliant: study
Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the “Bad Ad” program.
Forest asks investors to support board picks over Icahn’s
Fighting an attempted palace coup by major shareholder Carl Icahn, Forest Laboratories management asked investors to reject Icahn’s slate of board nominees in favor of the company’s own candidates.
Merck plans cuts of up to 13,000 jobs by the end of 2015
In an effort to further slim its budgetary waistline, Merck & Co., though having reported a 7% raise in sales during Q2, has announced plans to cut up to 13,000 jobs by the end of 2015, with up to 40% of reductions scheduled to occur in the US.
What will Google+ mean for healthcare advertisers?
In continuing to roll out its Facebook-like social media-based offerings, Google has launched a beta version of a new service called Google+, which strives to improve individual searches and allow users to connect on similar topics.
AI Deciphered: Discovering the Potential for Marketers and Communicators